Engineered yeast boosts lab production of CBD and CBDA

A study on the directed engineering and multiple transformations of cannabidiolic acid synthase to enhance the expression level of the recombinant enzyme.

Archives of microbiology • • Highly Relevant
🤖

AI Summary

Researchers engineered cannabidiolic acid synthase (CBDAS)—the enzyme involved in producing cannabidiolic acid (CBDA)—to work more effectively in yeast. The redesigned enzyme contained several targeted amino-acid changes, and computer modeling suggested that stronger molecular interactions and more contact points with its substrate may explain its improved catalytic activity.

In Pichia pastoris yeast, the engineered strain produced 71.543 ng/mL of CBDA and 75.163 ng/mL of CBD, representing increases of 11.87% and 11.53% over the comparison mutant. A second round of gene transformation further increased CBDA and CBD yields by 9.77% and 12.65%, respectively. Expression worked across a broad range of temperatures and pH levels, with the best results at 30°C and pH 6. These findings support future laboratory-scale, enzyme-based production of CBD, but they do not show effects in cannabis users or clinical benefits.

💡 Key Findings

1
A redesigned CBDAS mutant produced 11.87% more CBDA and 11.53% more CBD than the comparison mutant in yeast.
Moderate
55%
2
Performing two consecutive gene transformations increased CBDA and CBD yields by 9.77% and 12.65%, respectively, compared with a single transformation.
Moderate
55%
3
The recombinant yeast tolerated induction from 20 to 45°C and pH 3 to 9, with optimal expression at 30°C and pH 6.
Moderate
55%
4
The results provide technical support for in-vitro biosynthesis of CBD using engineered enzymes, rather than evidence of therapeutic effects for cannabis users.
Good
60%

📄 Original Abstract

To increase the activity of cannabidiolic acid synthase (CBDAS) and its expression levels in yeast, this study focused on the CBDASG183V-N482W mutant. Using computer-aided techniques and literature reviews, four mutation sites were further identified, resulting in the mutant CBDASH114E-S116A-C176Y-G183V-N328Q-N482W. The CBDAS gene was integrated into the Pichia pastoris genome via multiple transformation rounds, and relative enzyme activity was analyzed using high-performance liquid chromatography. The results of the molecular docking analysis revealed factors such as increased intermolecular forces, shorter bond lengths, and an increased number of amino acid-substrate interaction sites, which may have contributed to the enhanced catalytic activity of the mutant. The concentrations of CBDA and CBD produced by the CBDASH114E-S116A-C176Y-G183V-N328Q-N482W mutant were 71.543 ng/mL and 75.163 ng/mL, respectively, which were 11.87% and 11.53% greater than those produced by the CBDASG183V-N482W mutant. The recombinant CBDAS strain obtained after two consecutive transformations of the CBDASH114E-S116A-C176Y-G183V-N328Q-N482W vector presented the highest CBDAS expression levels and CBD and CBDA yields; compared with those obtained after a single transformation, the CBDA and CBD yields increased by 9.77% and 12.65%, respectively. In addition, the tolerance of the recombinant strain to induction culture conditions was analyzed, revealing that the strain could be induced to express the protein at temperatures ranging from 20 to 45 °C and at pH values ranging from 3 to 9, with optimal expression observed at 30 °C and pH 6. These findings provide theoretical and technical support for the production of enzyme preparations for the in vitro-directed biosynthesis of cannabidiol.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.